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Baseline differential blood count and prognosis in CD20-positive
post-transplant lymphoproliferative disorder in the prospective
PTLD-1 trial
Leukemia (2013) 27, 2102–2105; doi:10.1038/leu.2013.110
Post-transplant lymphoproliferative disorder (PTLD) is a spectrum
of lymphatic diseases associated with the use of potent
immunosuppressive drugs after transplantation and ranges from
polyclonal early lesions associated with primary Epstein-Barr virus
(EBV) infection to monomorphic lymphoma.1 The PTLD-1 trial, the
largest prospective phase II trial in the ﬁeld so far, has
demonstrated the efﬁcacy and safety of sequential therapy
(rituximab followed by cyclophosphamide, doxorubicin,
vincristin, prednisolone (CHOP) chemotherapy) with an overall
response rate (ORR) of 90% and 6.6 years median overall survival
(OS) in CD20-positive PTLD unresponsive to reduction of
immunosuppression.2 Because of the risk of treatment-related
complications, such as infections in immunosuppressed transplant
recipients, tailoring treatment to the individual patient is of
particular importance in PTLD.3 The European study groups on
PTLD have already implemented risk stratiﬁcation according to the
response to rituximab (NCT00590447), with encouraging interim
results.4 However, stratiﬁcation according to baseline parameters
could potentially improve therapy even further.
With this in mind, we have noted with interest that a number of
publications have demonstrated a signiﬁcant prognostic effect of
the differential blood count at initial diagnosis on OS in
immunocompetent patients with diffuse large B-cell lymphoma
(DLBCL): these included a poorer outcome in patients with an
absolute lymphocyte count (ALC)p1000/ml in DLBCL treated with
rituximab-cyclophosphamide, doxorubicin, vincristin, predniso-
lone (R-CHOP) immunochemotherapy,5–8 inferior OS and
progression-free survival (PFS) for patients with a baseline
neutrophil/lymphocyte ratio (NLR) X3.5 in a cohort of 255
consecutive patients with DLBCL treated with R-CHOP at a
single centre,9 and signiﬁcantly poorer treatment response, OS
as well as PFS, for patients with a lymphocyte-to-monocyte ratio
(LMR) p2.6 in 438 patients with DLBCL treated with R-CHOP.10 In
addition, Wilcox et al.8 demonstrated a poor OS outcome in a
cohort of 366 patients with DLBCL treated from 1993 to 2007 with
CHOP or R-CHOP at a single institution not only for a low ALC
p1000/ml but also for a high absolute monocyte count (AMC)
X630/ml, and combined both in a model, the absolute monocyte
and lymphocyte prognostic score (AMLPI), assigning one point each
for either low lymphocytes or high monocytes. This model
demonstrated a highly signiﬁcant effect on OS and PFS—
conﬁrmed in a subgroup analysis of those patients receiving
R-CHOP. The cohort of 70 patients treated in the PTLD-1 trial is the
largest prospectively treated trial cohort in this disease entity so far.
Because of uniform diagnostic criteria and treatment, it is ideally
suited to examine the prognostic value of the baseline differential
blood count in PTLD under sequential immunochemotherapy.
The current analysis is based on the published data set of the
international, prospective, multicentre phase II PTLD-1 trial
(NCT01458548, n¼ 70, data cut-off 1 June 2011):2 solid organ
transplant recipients with CD20-positive PTLD unresponsive to
immunosuppression reduction received four weekly courses of
375mg/m2 rituximab followed by 4 weeks without treatment
and four cycles of CHOP chemotherapy (cyclophosphamide
750mg/m2 IV day (d) 1, doxorubicin 50mg/m2 IV d1, vincristine
1.4mg/m2 IV d1 and prednisone 50mg/m2 Per OS (PO) d1–5) at 3-
week intervals starting at day 50. In case of disease progression
under rituximab treatment, patients proceeded to chemotherapy
immediately (therefore, starting before day 50). Supportive
treatment included granulocyte colony-stimulating factor support
(mandatory) as well as antibiotic prophylaxis (cotrimoxazole and
ciproﬂoxacin, recommended). Key exclusion criteria were central
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nervous system involvement, human immunodeﬁciency virus
infection, severe organ dysfunction not related to PTLD and Eastern
Cooperative Oncology Group (ECOG) performance status 42.
Baseline differential blood counts were collected retrospectively
from the recruiting centres. Baseline was deﬁned as within 4 weeks
before the ﬁrst application of rituximab. Overall, baseline differential
blood counts were available from 56/70 patients (80%) treated in
the PTLD-1 trial from centres in Australia, France and Germany.
Exploratory univariate analyses were performed by applying log-
rank analyses to Kaplan–Meier statistics for time-to-event out-
comes and w2-tests to categorical variables. Multivariable analyses
were performed using Cox regression models (likelihood ratio,
backward elimination). The level of signiﬁcance in all cases was set
at Po0.05. Statistical analysis was performed with IBM SPSS 20,
Armonk, NY, USA.
In a univariate analysis of the differential blood count at
diagnosis (Table 1), an ALC p1000 lymphocytes/ml (P¼ 0.027),
LMR p2.6 (P¼ 0.034) and a baseline NLR X3.5 (P¼ 0.006) were
associated with inferior OS. However, neither ALC, NLR nor LMR
had a signiﬁcant effect on time to progression (TTP).
Median lymphocyte counts (830/ml) and monocyte counts
(495/ml) were lower than those reported by Wilcox et al.8
in immunocompetent lymphoma patients (1230 and 630/ml,
respectively). Although ALC p1000/ml had a signiﬁcant
prognostic effect on OS (see above), AMC did not reach
prognostic signiﬁcance on OS or TTP as a dichotomized variable
in the PTLD-1 cohort (neither Wilcox’s cut-off of 630/ml nor a
cut-off at the median, 495/ml, Table 1). The AMLPI had no
signiﬁcant effect on OS (P¼ 0.093) or TTP (P¼ 0.433). However,
an adjusted AMLPI using a median monocyte cut-off (X495/ml)
in analogy to the situation in immunocompetent patients was
signiﬁcant for OS (P¼ 0.010) and borderline signiﬁcant for TTP
(P¼ 0.052, Table 1). The group of patients with an adjusted AMLPI
41 in particular had signiﬁcantly poorer OS (P¼ 0.016) and TTP
(P¼ 0.027) than those with a score p1 (Figure 1).
We have previously published multivariate Cox regression
analyses of factors affecting OS and TTP in the PTLD-1 trial and
found that time-to-PTLD was a signiﬁcant protective factor for
both OS and TTP and EBV association for TTP only.2 We performed
backward log-rank Cox regressions with highly signiﬁcant
variables from the univariate analyses (NLR X3.5, and adjusted
AMLPI for OS; adjusted AMLPI 41 for TTP) and the previously
established parameters age, time-to-PTLD, EBV association,
elevated serum LDH and ECOG X2. In these models, NLR X3.5
remained a signiﬁcant predictor of OS (P¼ 0.019, hazard ratio (HR)
3.701, 95% conﬁdence interval (CI) 1.242–11.030) and an adjusted
AMLPI 41 of TTP (P¼ 0.038, HR 2.936, 95% CI 1.062–8.119) in
multivariate analysis.
In PTLD, it is of particular importance to ascertain if inferior OS is
related to poor treatment efﬁcacy or treatment complications.
Table 1. Baseline differential blood count as prognostic factors in univariate analysis in the PTLD-1 trial
n/N (%) OS TTP
P HR (95% CI) P HR (95% CI)
ALC p1000/ml 34/56 (60.7) 0.027 2.809 (1.122–7.030) 0.104 2.538 (0.827–7.792)
AMC X630/ml 14/56 (25) 0.873 0.928 (0.372–2.314) 0.450 0.618 (0.178–2.153)
AMC X495/ml 28/56 (50) 0.251 1.580 (0.723–3.452) 0.387 1.532 (0.583–4.026)
LMR p2.6 37/56 (66.1) 0.034 2.891 (1.081–7.728) 0.106 2.798 (0.803–9.747)
NLR X3.5 36/56 (64.2) 0.006 4.479 (1.529–13.121) 0.169 2.198 (0.716–6.751)
AMLPI 16,32,8 of 56 0.093 1.668 (0.917–3.034) 0.433 1.342 (0.643–2.799)
Adjusted AMLPI 10,30,16 of 56 0.010 2.288 (1.222–4.282) 0.052 2.153 (0.992–4.673)
Adjusted AMLPI 41 16/56 (28.6) 0.016 2.642 (1.197–5.831) 0.027 2.949 (1.134–7.669)
Abbreviations: ALC, absolute lymphocyte count; AMC, absolute monocyte count; AMLPI, absolute monocyte and lymphocyte prognostic score; CI, confidence
interval; HR, hazard ratio; LMR, lymphocyte-monocyte ratio; n/N, number of patients with risk factor over number of patients analysed; NLR, neutrophil/
lymphocyte ratio; OS overall survival; PTLD, post-transplant lymphoproliferative disorder; TTP, time to progression. AMLPI, one point each for low
lymphocytes (ALCp1000/ml) and high monocytes (AMCX630/ml); adjusted AMLPI, one point each for low lymphocytes (ALCp1000/ml) and high monocytes
(AMC X495/ml). Significant results (Po0.05) are highlighted in bold.
Figure 1. Kaplan–Meier estimates of TTP (a) and OS (b) in 56 PTLD patients treated with sequential immunochemotherapy in the PTLD-1 trial
stratified by an adjusted absolute monocyte and lymphocyte prognostic index (adjusted AMLPI, one point each for low lymphocytes (ALC
p1000/ml) and high monocytes (AMCX495/ml)). The solid line indicates a score of 0, the broken line indicates a score of 1 and the dashed line
indicates a score of 2.
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Furthermore, the differential blood count in an immuno-
suppressed patient is strongly inﬂuenced by their medication.
We therefore investigated correlations between the ALC, NLR, LMR
and adjusted AMLPI on the one hand and ORR, treatment-related
mortality (TRM) and immunosuppressant drug classes (antimeta-
bolites, mammalian target of rapamycin inhibitors, calcineurin
inhibitors and steroids) on the other hand:
There were no signiﬁcant correlations between TRM and
either ALC p1000/ml, NLR X3.5, LMR p2.6 or the adjusted
AMLPI. In immunocompetent DLBCL patients, a lower ORR
for patients with ALC p1000/ml has been described;5,7 however,
in our PTLD cohort, there was no signiﬁcant correlation between
ALC p1000/ml, NLR X3.5, LMR p2.6 or the adjusted AMLPI
with ORR to either rituximab or sequential immunochemotherapy.
Regarding immunosuppression, steroids were signiﬁcantly
more common in patients with a NLR X3.5 (27/35 vs 10/20,
P¼ 0.039). We could not identify signiﬁcant correlations between
ALC p1000/ml, LMR p2.6 or adjusted AMLPI and immuno-
suppression.
In summary, in 56/70 patients treated in the PTLD-1 trial, ALC
p1000/ml, NLR X3.5, LMR p2.6 and an adjusted AMLPI were
signiﬁcantly associated with inferior OS in univariate analysis. NLR
X3.5 was an independent signiﬁcant predictor of OS in multi-
variate analysis. Only an adjusted AMLPI 41 had a signiﬁcant
effect on TTP in univariate and multivariate analysis. None of the
examined counts or ratios had an effect on the risk of TRM or ORR.
Of note, a NLR X3.5 was signiﬁcantly correlated with steroid-
containing immunosuppression.
In this journal, Wilcox et al. have recently discussed the
theoretical basis for using peripheral myeloid and lymphoid
lineage cells as biomarkers for tumour microenvironment and host
immunity in immunocompetent patients with DLBCL.8 We were
surprised to make similar prognostic observations in PTLD, despite
the effects of immunosuppressive drugs not only on leukocyte
counts but also on leukocyte, particularly lymphocyte, function.
Our observations suggest that the baseline differential blood
count integrates information about tumour microenvironment,
host immunity and the level of immunosuppression. The
signiﬁcant effect of NLR, ALC and LMR on OS, but not TTP,
could suggest a contribution of additional, non-tumour-related
factors. Such factors might include infection as well as
cardiovascular disease. PTLD patients (heart- and kidney-trans-
plant recipients in particular) are at high risk of cardiovascular
events, and high NLR has been linked to poorer OS in patients
with coronary artery disease.11
This retrospective analysis of a subgroup of patients from the
largest phase II trial in PTLD so far demonstrates a potential
independent prognostic role of the baseline differential blood
count, a ubiquitously available and cheap investigation in the
setting of post-transplant lymphoma. However, because of the
limitations of multiple testing in a small cohort, prospective
validation in an independent cohort will be required before
incorporation into stratiﬁcation protocols.
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Distribution of genomic breakpoints in chronic myeloid leukemia:
analysis of 308 patients
Leukemia (2013) 27, 2105–2107; doi:10.1038/leu.2013.116
Translocation breakpoints of several types of leukemia have been
sequenced in order to identify factors that lead to DNA breakage
(for example, topoisomerase 2 in MLL and PML-RARA leukemia).1,2
Several studies in chronic myeloid leukemia (CML) have shown a
possible association of breakpoints with ALU interspersed repeat
elements (IREs),3–6 but remained inconclusive due to their small
sample size. We sequenced 308 BCR–ABL1 fusion genes and
performed a bioinformatic analysis with greater statistical power
to identify breakpoint motifs.
The research was approved by the ethics committees of the
participating institutions. All CML patients in this study expressed
BCR–ABL1 mRNA with breakpoints in the major breakpoint cluster
region of BCR. The BCR–ABL1 genomic breakpoint was identiﬁed
using one of three methods: long range,7 short range8 or inverse
PCR.9 These methods rely on the fact that BCR breakpoints are tightly
clustered, so that using a limited number of BCR primers it should be
possible to amplify across the BCR–ABL1 junction. The success rates
of the three methods were around 90%, 99% and 65%, respectively.
The use of several methods with a high overall success rate avoids
skewing of the data due to the limitations of a speciﬁc technique (for
example, restriction enzyme sites). The data of 32 patients and ﬁve
common CML cell lines were previously published.7,10
In BCR there were 129 breakpoints between exon 13 and the
end of exon 14 (giving rise to e13a2 mRNA), and 179 breakpoints
between exon 14 and the end of exon 15 (e14a2 mRNA)
(Figure 1a). Ten breakpoints were in BCR exons: in these cases,
the partial exon was spliced out of the mRNA. In ABL1 256
breakpoints were located in the large intron between the ﬁrst
alternative exon 1b and the second alternative exon 1a. Thirty-
eight breakpoints were located in the smaller intron between exon
1a and exon 2 (Figure 1b). Two breakpoints were in the short intron
between exon 2 and exon 3, resulting in the expression of
e13a3 BCR–ABL1 mRNA. Twelve breakpoints were in a region of
B10 kb upstream of ABL1 extending from the last exon of the
EXOSC2 gene. No breakpoints were found in ABL1 exons. A modiﬁed
Anderson–Darling test showed non-uniformity of distribution of BCR
breakpoints (Po10 5), but not ABL1 breakpoints (P40.05).11
MEME software was used to search for sequence motifs that
might be over-represented in the vicinity of breakpoints (10 bp
up- and downstream of BCR breaks, and 100 bp around ABL1
breaks).12 Where sequence neighborhoods overlapped for
multiple breakpoints, the contiguous intervals were combined
resulting in 34 distinct sequences in BCR, and 195 sequences in
ABL1. The de novo search in ABL1 returned only motifs resulting
from the presence of IREs, while no motifs were over-represented
in BCR, despite the signiﬁcantly non-uniform distribution of
breakpoints in BCR. The ABL1 gene is rich in ALU and other IREs,
which together make up B50% of the entire ABL1 breakpoint
region, and it has been proposed that these elements are
somehow involved in the genesis of the BCR–ABL1 fusion. ALU
and L1 are the two most frequent types of IRE in the ABL1
breakpoint region, accounting for more than half of all repeats. In
the relevant portion of BCR there is a single ALU repeat contiguous
with an L1 repeat, and two small L2 repeats. We calculated the
interval between each ABL1 breakpoint and the nearest ALU or L1
repeat and obtained a quantile–quantile (QQ) plot by comparing
this distribution of intervals with a reference distribution (all
203 384 intervals between every nucleotide in the 203 kb
reference sequence and its nearest repeat). This was also done
for 1000 sets of 308 uniformly selected ‘breaks’ in place of the
actual breakpoints to determine an approximate envelope of QQ
plots under uniformity. The distribution of intervals for the CML
patients lay within this envelope (Supplementary Figures),
indicating that BCR–ABL1 breakpoints are no more frequent than
would be expected in and around these IREs.
The de novo search for motifs resulted in the discovery in ABL1
of a large palindrome with 243 bp of perfect reverse comple-
mentarity separated by B2 kb (Figure 1b). It is difﬁcult to assign
statistical signiﬁcance to this observation, but within the whole
141Mb of chromosome 9 there are only eight such palindromes
with arm lengths of X200 bp and loop lengths of o2 kb. In BCR,
the nearest palindrome was downstream of exon 16, with an arm
length of 100 bp and a loop length ofB3.6 kb. In chromosome 22,
there are 23 palindromes of comparable size and separation.
Palindromic sequences can result in non-B DNA conformation and
have been associated with pathogenic recombination in
humans.13 It is possible that secondary structures in DNA are
involved in initiating an interaction between chromosomes 9 and
22, as postulated for a 76 kb duplicon in 9q34 and 22q11.2.14
We searched for 50 sequence motifs previously reported in
association with DNA breakpoints (Supplementary Data). For every
breakpoint, we determined the shortest distance between the
breakpoint and each of the 50 motifs, upstream and downstream
and on both genomic strands. These were compared (via QQ
plots) with similar distances for cyclic permutations of the motifs,
so as to reduce the effects of polynucleotide composition. None of
the motifs was signiﬁcantly associated with BCR–ABL1 breakpoints.
Analysis of the breakpoint sequences showed an increase in the
frequency of microhomology, a hallmark of non-homologous end-
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